SELLAS Receives Fast Track Designation from FDA for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
283
SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq: SLS ) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead asset, galinpepimut-S (GPS), for the treatment of multiple myeloma (MM). GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.

The Company reported final clinical and immunological data from a Phase 2 clinical trial for GPS in the treatment of high-risk multiple myeloma at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting on March 19, 2018.

The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions that have the potential to address unmet medical needs.  A product candidate with Fast Track status is afforded greater access to the FDA for the purpose of expediting the product candidate’s development, review and potential approval.  For a product candidate with Fast Track designation, the FDA may consider sections of its Biologics License Application (BLA) for review on a rolling basis before the complete application is submitted if relevant criteria are met.

“The designation of Fast Track for GPS represents important recognition by the FDA of the potential of this novel immunotherapeutic to address the significant unmet need in the treatment of patients with high-risk multiple myeloma in patients with poor-risk cytogenetics at diagnosis who still harbor minimal residual disease (MRD) after autologous stem cell transplant,” said Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer of SELLAS.  “We are fully committed to working closely with the FDA as we continue development of our potential first-in-class novel WT1-targeting cancer vaccine for select high-risk MM patients in the post-autotransplant maintenance setting after standard first-line treatment.”

About the Phase 2 GPS multiple myeloma study

The open-label Phase 2 study consisted of 19 patients with multiple myeloma who had high-risk cytogenetics at initial diagnosis and remained at least minimal residual disease (MRD)-positive after a successful autologous stem cell transplant (“ASCT”).  GPS was administered to patients in the study who achieved a stable disease or better status (per International Myeloma Working Group criteria) following ASCT. GPS was evaluated as consolidation therapy to potentially stimulate a highly-specific immune response against WT1 in order to prevent or delay myeloma progression. Median progression-free survival (PFS) of 23.6 months was reported in the high-risk disease setting, compared to historically inferior outcomes while on an immunomodulatory drug (IMID) or proteasome inhibitor post-ASCT maintenance.  Median overall survival has not been reached to date. GPS stimulated time-dependent and robust CD4+ T cell or CD8+ T cell immune responses (IRs) specific for all four WT1 peptides within GPS, two of which are heteroclitic (mutated, by design).  In addition, GPS stimulated similar IRs against the two counterpart native peptides. The IRs were confirmed in up to 91% of patients across HLA allele types, with multivalent IRs emerging in up to 64% of patients.  Multifunctional cross-epitope T cell reactivity was observed in 75% of patients to antigenic epitopes against which hosts were not specifically immunized, in a pattern akin to epitope spreading.  A link of clinical activity to antigen-specific immune responses was suggested.

About Galinpepimut-S (GPS): GPS is a heteroclitic multivalent, multi-peptide cancer immunotherapeutic agent composed of four peptides, addressing over 20 epitopes, and derived from the WT1 protein, which has been ranked by the National Cancer Institute as a top priority among cancer antigens for immunotherapy.  Importantly, because the WT1 antigen is overexpressed in many malignancies, and is not found in most normal tissues, GPS has the potential to be a broad immunotherapy, effective across a multitude of diverse cancer types and patient populations. 

About SELLAS: SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.  GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications.  SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma (MM) and ovarian cancer.  SELLAS plans to study GPS in up to four additional indications.  SELLAS has received Orphan Drug designations for GPS from the U.S. Food & Drug Administration (FDA) for AML, MPM, and MM, as well as from the European Medicines Agency, for AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA. SELLAS’ second product candidate, NeuVax™ (nelipepimut-S), is a HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NeuVax™ has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care.

For more information on SELLAS, please visit  www.sellaslifesciences.com

Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to the results of clinical studies and as to further development of GPS for ovarian cancer as well as for a broad range of cancer indications, including the timing of clinical trials. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs. These risks and uncertainties are described more fully in SELLAS’ Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact: Will O’Connor Stern Investor Relations, Inc. 212-362-1200 ir@sellaslife.com  

David Moser, JD Sellas Life Sciences Group 813-864-2571 info@sellaslife.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 43

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 85

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 19

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 294

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 164

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Cryptocurrency Through Sustainable Mining Solutions

Updated Category News Views 132

Ripple and Dogecoin Capture Market Attention Recently, Ripple, known by its trading symbol XRP, regained significant visibility in the cryptocurrency market following a major legal victory against a regulatory body. This resurgence has reignited interest among investors and enthusiasts alike. Meanwhile, Dogecoin has been experiencing a renaissance, driven by the ambitious...

Continue Reading
General Dynamics Sees Growth in Q2 Earnings and Revenue

Updated Category News Views 147

General Dynamics Q2 Financial Highlights General Dynamics reported remarkable financial results for the second quarter of 2025, showcasing a revenue of $13 billion, which marks an 8.9% increase compared to the same quarter last year. The company achieved operating earnings of $1.3 billion, translating to a diluted earnings per share (EPS) of $3.74, reflecting a 14.7%...

Continue Reading
FIU Shines as a Top Public University in New Ranking

Updated Category News Views 77

FIU Ranks High in TIME's New College List Alright, listen up. The latest college buzz isn't just noise—Florida International University (FIU) is sitting pretty at No. 23 among public universities in TIME's first crack at America's Best Colleges for the 2026-2027 term. They're also punching in at No. 62 overall out of 500 schools. For a university that's been...

Continue Reading
Recent Net Asset Value Disclosure for Hargreave Hale AIM VCT

Updated Category News Views 174

Understanding the Latest Net Asset Value Announcement The Hargreave Hale AIM VCT PLC has recently made an important announcement regarding its Net Asset Value (NAV). This provides valuable insights for investors and stakeholders looking to evaluate the fund's performance. It is crucial for those following this investment vehicle to stay informed about NAV updates, as...

Continue Reading
Orvana Minerals Corp. Reports Financial Results for Q1 FY2026

Updated Category News Views 191

Orvana Minerals Corp. Financial Performance Overview TSX:ORV Orvana Minerals Corp. (TSX: ORV) has recently disclosed its financial statements for the first quarter of the fiscal year 2026 through its subsidiary, Empresa Minera Paitití, S.A. (EMIPA). These unaudited results are now available for viewing on the Bolivian stock market. The disclosure marks an important...

Continue Reading